Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna T...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

Murphydingle Apr. 2 at 7:45 PM

$NTLA nasty pump and dumper

3 · Reply

burbs88 Apr. 2 at 7:07 PM

$NTLA Potential inverse head and shoulders bottom over a one week time frame.👀

0 · Reply

APman Apr. 2 at 3:28 PM

$NTLA Will it squeeze?

0 · Reply

APman Apr. 2 at 2:38 PM

$NTLA Huh?

0 · Reply

Bonniee36 Apr. 2 at 2:20 PM

$NTLA gene editing names need patience but this one is perking

0 · Reply

APman Apr. 2 at 1:25 PM

$NTLA Any prediction on todays low? I say 12.5

1 · Reply

Picklez_ Apr. 2 at 11:45 AM

$NTLA pump and dump to return shares 🤣

0 · Reply

Murphydingle Apr. 2 at 10:56 AM

$NTLA told ya. pump and dump to commence hard today

0 · Reply

sgsam Apr. 1 at 7:45 PM

$NTLA me too

0 · Reply

MarketILF Apr. 1 at 7:21 PM

$NTLA just blocked Murphy idiot. Refreshing.

1 · Reply

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 7:30 AM EST - 4 weeks ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 2, 2026, 10:05 AM EST - 4 weeks ago

Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial

Mar 2, 2026, 7:40 AM EST - 4 weeks ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:30 AM EST - 4 weeks ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026, 9:47 PM EST - 5 weeks ago

Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:30 AM EST - 5 weeks ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 24, 2026, 8:00 AM EST - 5 weeks ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Feb 19, 2026, 7:30 AM EST - 6 weeks ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 5, 2026, 1:55 PM EST - 2 months ago

Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026

Jan 27, 2026, 1:03 PM EST - 2 months ago

Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder

Jan 27, 2026, 8:13 AM EST - 2 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 14, 2026, 2:16 PM EST - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 7:30 AM EST - 3 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 11:34 AM EST - 4 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR HIMS HTZ LCID REPL SOC WEN

Nov 10, 2025, 3:17 PM EST - 5 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 5 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 7, 2025, 5:46 AM EST - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 5:11 PM EDT - 5 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 11:17 AM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Oct 27, 2025, 7:38 AM EDT - 5 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 24, 2025, 8:15 AM EDT - 5 months ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Sep 25, 2025, 1:57 PM EDT - 6 months ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 9:52 AM EDT - 6 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 19, 2025, 2:31 PM EDT - 7 months ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 18, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 7 months ago

Why big players are pouring millions in THIS biotech stock

Aug 15, 2025, 12:24 PM EDT - 8 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 7, 2025, 8:17 PM EDT - 8 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 30, 2025, 11:07 AM EDT - 8 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

Jul 18, 2025, 8:00 AM EDT - 9 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jun 15, 2025, 10:45 AM EDT - 10 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

May 29, 2025, 11:25 AM EDT - 11 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 20, 2025, 5:47 AM EDT - 11 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

May 18, 2025, 7:25 AM EDT - 11 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 14, 2025, 1:57 PM EDT - 11 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 12, 2025, 9:07 AM EDT - 11 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 8, 2025, 11:37 AM EDT - 11 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:44 AM EDT - 11 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Murphydingle Apr. 2 at 7:45 PM

$NTLA nasty pump and dumper

3 · Reply

burbs88 Apr. 2 at 7:07 PM

$NTLA Potential inverse head and shoulders bottom over a one week time frame.👀

0 · Reply

APman Apr. 2 at 3:28 PM

$NTLA Will it squeeze?

0 · Reply

APman Apr. 2 at 2:38 PM

$NTLA Huh?

0 · Reply

Bonniee36 Apr. 2 at 2:20 PM

$NTLA gene editing names need patience but this one is perking

0 · Reply

APman Apr. 2 at 1:25 PM

$NTLA Any prediction on todays low? I say 12.5

1 · Reply

Picklez_ Apr. 2 at 11:45 AM

$NTLA pump and dump to return shares 🤣

0 · Reply

Murphydingle Apr. 2 at 10:56 AM

$NTLA told ya. pump and dump to commence hard today

0 · Reply

sgsam Apr. 1 at 7:45 PM

$NTLA me too

0 · Reply

MarketILF Apr. 1 at 7:21 PM

$NTLA just blocked Murphy idiot. Refreshing.

1 · Reply

Picklez_ Apr. 1 at 6:47 PM

$NTLA the sky is falling, were 90% institutionally owned, up 3% on 1.8mil shares traded today, sell it all and burn it to the ground, it's all over 🤣

0 · Reply

Murphydingle Apr. 1 at 6:23 PM

$NTLA here comes the roll over, big trump speech tonight, look out below

0 · Reply

Murphydingle Apr. 1 at 5:53 PM

$NTLA Everyone all bulled back up on this bear market rally, shorts just licking their chops again, get ready for the next leg down, nasty stuff

0 · Reply

Picklez_ Apr. 1 at 4:28 PM

$NTLA seems like all the butt lickers disappeared

0 · Reply

LongT Apr. 1 at 1:51 PM

$NTLA Nice day trade this morning but under 1 mil vol still. 35% short interest . Little pops being controlled with small amount of shorting. Doubt we see much until after holiday weekend.

0 · Reply

burbs88 Apr. 1 at 12:09 PM

$NTLA A lot of reasons this is <15. None of the reasons are sustainable, long term reasons. None of them are good reasons. $60 late 2027

0 · Reply

cseo12 Apr. 1 at 4:01 AM

$NTLA After HAE result release, invivo will be the future of bio tech.

0 · Reply

cseo12 Apr. 1 at 3:59 AM

$NTLA After HAE data release, invivo technology will be the future of bio tech.

0 · Reply

CRSPbacon Apr. 1 at 2:47 AM

$NTLA

0 · Reply

cdewder Mar. 31 at 8:31 PM

$NTLA Funds had $34B in compulsory buying for rebalancing in the markets today. Nice to be needed but it would be great to be wanted again.

0 · Reply

Murphydingle Mar. 31 at 7:33 PM

$NTLA lmao yeah i bet

0 · Reply

Murphydingle Mar. 31 at 7:33 PM

$NTLA crazy ass pump and dumb, back way down tomorrow

0 · Reply

Market Cap	1.55B
Revenue (ttm)	67.67M
Net Income (ttm)	-412.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-609.86%
Debt to Equity Ratio	0.00

Volume	2,750,400
Avg Vol	4,430,702
Day's Range	N/A - N/A
Shares Out	118.13M
Stochastic %K	63%
Beta	1.99
Analysts	Sell
Price Target	$24.67